Due to an error in the editorial process, an incorrect version of the article was published. Significant textual revisions to the published article are detailed below.
The previous version is available in the Supplementary Material of this Erratum. The article has now been updated with the correct version. The publisher apologizes for this error.
A correction has been made to the section “Primary Drug Resistance”, subsection “Epidermal growth factor receptor (EGFR)”. This section has been removed and its contents merged with the section entitled “Tumor heterogeneity and EGFR”.
A correction has been made to the section “Acquired Drug Resistance”, subsection “PI3K/AKT and MAPK/ERK signaling pathways”. This section has been removed and replaced with the section entitled “EGFR and HGF/cMet mediated signaling pathway”.
A spelling mistake was corrected in the keywords section of this article. “Carcinom” was corrected to “carcinoma”.
Additional references have been added to the published article. Details of these references can be found in the "References" section of this article.
Tables 1, 2 have been added to the published article.
TABLE 1
| Drug | Type of drug resistance | Mechanism of drug resistance | Reasons responsible | References |
|---|---|---|---|---|
| sorafenib | Primary drug resistance | Mutation of EGFR | Dysregulation of EGFR and HER-3 | Hsieh et al. (2111) |
| Enrichment of CSC | LSD1 and activation of β-catenin | Lei et al. (2015) | ||
| EPHB2/TCF1/EPHB2/β-catenin | Leung et al. (2021) | |||
| Acquired drug resistance | compensatory activation of the PI3K/Akt pathway | Activation of Akt | Chen et al. (2011) | |
| compensatory activation of the MAPK/ER K pathway | Production of HGF and phosphorylation of c-Met | Han et al. (2017) | ||
| EMT | Ets- 1-GPX2 | Gluck et al. (2019) | ||
| TNF-α/NF-κB/EMT | Tan et al. (2019) | |||
| Metabolic reprogramming | Activation of Rate limiting enzyme | Li et al. (2017) | ||
| PI3K/Akt/HIF- 1α | Zhang et al. (2020) | |||
| HDAC11/LKB1 | Bi et al. (2021) | |||
| Autophagy | The protective effect of autophagy | Lu et al. (2018),Tong et al. (2018),Lin et al. (2020b) | ||
| The pro-death mechanism of autophagy | Neophytou et al. (2021) | |||
| Non-coding RNAs | MicroRNAs and LncRNAs | Table 2 | ||
| Evasion of apoptosis | Deficiency of PUMA | Dudgeon et al. (2012) | ||
| Highly expression of FGFR4 | Repana and Ross (2015) | |||
| Dysregulation of cell cycle control | E2F1-Rb-cyclin E1 | Hsu et al. (2016) | ||
| Lenvatinib | Primary drug resistance | Activation of FGFR1/FGFR/VEGFR | High levels of FGFR1 | Yamauchi et al. (2020) |
| Enrichment of CSC | CD73-SOX9 | Ma et al. (2020) | ||
| Acquired drug resistance | High levels of EGFR | EGFR/PAK2/ERK5 | Jin et al. (2021) | |
| Loss of NF1 and DUSP9 | PI3K/AKT and MAPK/ERK | Lu et al. (2021) | ||
| Non-coding RNAs | LncRNA MT1JP | Yu et al. (2021) | ||
| LncRNA XIST | Duan et al. (2022) | |||
| circMED27 | Zhang et al. (2021) | |||
| regorafenib | Acquired drug resistance | EMT | Pin1/Gli1/Snail/E-cadhe rin | Wang et al. (2019) |
| SphK2 | NF-κB and activation of STAT3 | Shi et al. (2020) | ||
| Activation of TGF-β signaling | Wnt/β-catenin | Karabicici et al. (2021) | ||
| TOP2A | Wnt/β-catenin | Wang et al. (2022) | ||
| cabozantinib | Primary drug resistance | Low levels of c-Met | C-Met | Gao et al. (2021) |
Summary of previous studies with the mechanisms of receptor tyrosine kinase drug resistance in HCC.
TABLE 2
| Name | Effects on sorafenib resistance | Target | Reference |
|---|---|---|---|
| miR-622 | Inhibiting | KRAS | Dietrich et al. (2018) |
| miR-7 | Inhibiting | TYRO3 | Kabir et al. (2018) |
| miR-486-3p | Inhibiting | FGFR4/EGFR | Ji et al. (2020) |
| miR-138-1-3p | Inhibiting | PAK5 | Li et al. (2021) |
| miR-122 | Inhibiting | IGF-1R | Xu et al. (2016) |
| miR-378a-3p | Inhibiting | IGF-1R | Lin et al. (2020a) |
| miR-32-5p | Promoting | PTEN | Fu et al. (2018) |
| miR-21 | Promoting | LncRNA SNHG1 | Li et al. (2019) |
| miR-140-5p | Inhibiting | lncRNA MALAT1 | Fan et al. (2020) |
Previous studies that show the involvement of miRNAs in sorafenib resistance in HCC.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1188062/full#supplementary-material
References
1
AraiH.BattaglinF.WangJ.LoJ. H.SoniS.ZhangW.et al (2019). Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat. Rev.81, 101912. 10.1016/j.ctrv.2019.101912
2
BiL.RenY.FengM.MengP.WangQ.ChenW.et al (2021). HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res.81 (8), 2015–2028. 10.1158/0008-5472.CAN-20-3044
3
ChenK. F.ChenH. L.TaiW. T.FengW. C.HsuC. H.ChenP. J.et al (2011). Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Ex. Ther.337 (1), 155–161. 10.1124/jpet.110.175786
4
Dagogo-JackI.ShawA. T. (2018). Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol.15 (2), 81–94. 10.1038/nrclinonc.2017.166
5
DietrichP.KochA.FritzV.HartmannA.BosserhoffA. K.HellerbrandC. (2018). Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut67 (7), 1328–1341. 10.1136/gutjnl-2017-315402
6
DuanA.LiH.YuW.ZhangY.YinL. (2022). Long noncoding RNA XIST promotes resistance to lenvatinib in hepatocellular carcinoma cells via epigenetic inhibition of NOD2. J. Oncol.2022, 4537343. 10.1155/2022/4537343
7
DudgeonC.PengR.WangP.SebastianiA.YuJ.ZhangL. (2012). Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene31 (46), 4848–4858. 10.1038/onc.2011.644
8
DuffyA. G.GretenT. F. (2017). Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol.14 (3), 141–142. 10.1038/nrgastro.2017.7
9
FanL.HuangX.ChenJ.ZhangK.GuY. H.SunJ.et al (2020). Long noncoding RNAMALAT1 contributes to sorafenib resistance by targeting miR-140-5p/aurora-A signaling in hepatocellular carcinoma. Mol. Cancer Ther.19 (5), 1197–1209. 10.1158/1535-7163.MCT-19-0203
10
FuX.LiuM.QuS.MaJ.ZhangY.ShiT.et al (2018). Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J. Exp. Clin. Cancer Res.37 (1), 52. 10.1186/s13046-018-0677-7
11
GaoC.WangS.ShaoW.ZhangY.LuL.JiaH.et al (2021). Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma. Front. Med.
12
GluckC.GlatharA.TsompanaM.NowakN.Garrett-SinhaL. A.BuckM. J.et al (2019). Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma. PLoS Genet.15, e1008250. 10.1371/journal.pgen.1008250
13
HanP.LiH.JiangX.ZhaiB.TanG.ZhaoD.et al (2017). Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Mol. Oncol.11 (3), 320–334. 10.1002/1878-0261.12039
14
HsiehS. Y.HeJ. R.HsuC. Y.ChenW. J.BeraR.LinK. Y.et al (2111). Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology53 (2), 504–516. 10.1002/hep.24083
15
HsuC.LinL. I.ChengY. C.FengZ. R.ShaoY. Y.ChengA. L.et al (2016). Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through mcl-1 suppression. Clin. Cancer Res.22 (10), 2555–2564. 10.1158/1078-0432.CCR-15-0499
16
HuangM.ChenC.GengJ.HanD.WangT.XieT.et al (2017). Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett.398, 12–21. 10.1016/j.canlet.2017.03.038
17
IppolitoM. R.MartisV.MartinS.TijhuisA. E.HongC.WardenaarR.et al (2021). Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Dev. Cell56 (17), 2440–2454. 10.1016/j.devcel.2021.07.006
18
ItoY.TakedaT.SakonM.TsujimotoM.HigashiyamaS.NodaK.et al (2001). Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer84 (10), 1377–1383. 10.1054/bjoc.2000.1580
19
JiL.LinZ.WanZ.XiaS.JiangS.CenD.et al (2020). miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis.11 (4), 250. 10.1038/s41419-020-2413-4
20
JinH.ShiY.LvY.YuanS.RamirezC. F. A.LieftinkC.et al (2021). EGFR activation limits the response of liver cancer to lenvatinib. Nature595 (7869), 730–734. 10.1038/s41586-021-03741-7
21
KabirT. D.GandaC.BrownR. M.BeveridgeD. J.RichardsonK. L.ChaturvediV.et al (2018). A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology67 (1), 216–231. 10.1002/hep.29478
22
KarabiciciM.AzbazdarY.OzhanG.SenturkS.Firtina KaragonlarZ.ErdalE. (2021). Changes in wnt and TGF-β signaling mediate the development of regorafenib resistance in hepatocellular carcinoma cell line HuH7. Front. Cell Dev. Biol.9, 639779. 10.3389/fcell.2021.639779
23
LeiZ. J.WangJ.XiaoH. L.GuoY.WangT.LiQ.et al (2015). Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5 + liver cancer initiating cells by suppressing negative regulators of β-catenin signaling. Oncogene34 (24), 3188–3198. 10.1038/onc.2015.182
24
LeungH. W.LeungC. O. N.LauE. Y.ChungK. P. S.MokE. H.LeiM. M. L.et al (2021). EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res.81 (12), 3229–3240. 10.1158/0008-5472.CAN-21-0184
25
LiS.DaiW.MoW.LiJ.FengJ.WuL.et al (2017). By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int. J. Cancer141 (12), 2571–2584. 10.1002/ijc.31022
26
LiW.DongX.HeC.TanG.LiZ.ZhaiB.et al (2019). LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res.38 (1), 183. 10.1186/s13046-019-1177-0
27
LiT. T.MouJ.PanY. J.HuoF. C.DuW. Q.LiangJ.et al (2021). MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway. J. Biomed. Sci.28 (1), 56. 10.1186/s12929-021-00752-4
28
LinZ.XiaS.LiangY.JiL.PanY.JiangS.et al (2020a). LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics10 (19), 8834–8850. 10.7150/thno.45158
29
LinZ.NiuY.WanA.ChenD.LiangH.ChenX.et al (2020b). RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J.39 (12), e103181. 10.15252/embj.2019103181
30
LuS.YaoY.XuG.ZhouC.ZhangY.SunJ.et al (2018). CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis.9 (6), 646. 10.1038/s41419-018-0681-z
31
LuY.ShenH.HuangW.HeS.ChenJ.ZhangD.et al (2021). Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discov.7 (1), 359. 10.1038/s41420-021-00747-y
32
MaX. L.HuB.TangW. G.XieS. H.RenN.GuoL.et al (2020). CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J. Hematol. Oncol.13 (1), 11. 10.1186/s13045-020-0845-z
33
McGranahanN.SwantonC. (2017). Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell168 (4), 613–628. 10.1016/j.cell.2017.01.018
34
NegriniS.GorgoulisV. G.HalazonetisT. D. (2010a). Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol.11 (3), 220–228. 10.1038/nrm2858
35
NegriniS.GorgoulisV. G.HalazonetisT. D. (2010b). Clonal heterogeneity and tumor evolution: Past, present, and the future. Nat. Rev. Mol. Cell Biol.11 (3), 220–228. 10.1038/nrm2858.14.McGranahan
36
NeophytouC. M.TrougakosI. P.ErinN.PapageorgisP. (2021). Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel)13 (17), 4363. 10.3390/cancers13174363
37
O'ConnorR.ClynesM.DowlingP.O'DonovanN.O'DriscollL. (2007). Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. Expert Opin. Drug Metab. Toxicol.3 (6), 805–817. 10.1517/17425255.3.6.805
38
PanJ.ZhangM.DongL.JiS.ZhangJ.ZhangS.et al (2022). Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy7, 1–15. 10.1080/15548627.2022.2117893
39
RepanaD.RossP. (2015). Targeting FGF19/FGFR4 pathway: A novel therapeutic strategy for hepatocellular carcinoma. Diseases3 (4), 294–305. 10.3390/diseases3040294
40
ShiW.ZhangS.MaD.YanD.ZhangG.CaoY.et al (2020). Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma. Front. Oncol.10, 694. 10.3389/fonc.2020.00694
41
TanW.LuoX.LiW.ZhongJ.CaoJ.ZhuS.et al (2019). TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine40, 446–456. 10.1016/j.ebiom.2018.12.047
42
TongM.CheN.ZhouL.LukS. T.KauP. W.ChaiS.et al (2018). Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J. Hepatol.69 (4), 826–839. 10.1016/j.jhep.2018.05.034
43
VasanN.BaselgaJ.HymanD. M. (2019). A view on drug resistance in cancer. Nature575 (7782), 299–309. 10.1038/s41586-019-1730-1
44
VishnoiK.KeR.ViswakarmaN.SrivastavaP.KumarS.DasS.et al (2022). Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma. Cell Death Dis.13 (7), 581. 10.1038/s41419-022-05022-1
45
WangJ.ZhangN.HanQ.LuW.WangL.YangD.et al (2019). Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Lett.444, 82–93. 10.1016/j.canlet.2018.12.010
46
WangZ.ZhuQ.LiX.RenX.LiJ.ZhangY.et al (2022). TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. Am. J. Cancer Res.12 (9), 4343–4360.
47
XuY.HuangJ.MaL.ShanJ.ShenJ.YangZ.et al (2016). MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett.371 (2), 171–181. 10.1016/j.canlet.2015.11.034
48
YamauchiM.OnoA.IshikawaA.KodamaK.UchikawaS.HatookaH.et al (2020). Tumor fibroblast growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma. Clin. Transl. Gastroenterol.11 (5), e00179. 10.14309/ctg.0000000000000179
49
YuT.YuJ.LuL.ZhangY.ZhouY.ZhouY.et al (2021). MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cell Oncol. (Dordr).44 (4), 821–834. 10.1007/s13402-021-00605-0
50
ZhangX.WuL.XuY.YuH.ChenY.ZhaoH.et al (2020). Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. Cancer Lett.481, 32–44. 10.1016/j.canlet.2020.03.027
51
ZhangP.SunH.WenP.WangY.CuiY.WuJ. (2021). circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol. Ther. Nucleic Acids27, 293–303. 10.1016/j.omtn.2021.12.001
Summary
Keywords
hepatocellular carcinoma, drug resistance, sorafenib, lenvatinib, regorafenib, cabozantinib
Citation
Frontiers Production Office (2023) Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front. Pharmacol. 14:1188062. doi: 10.3389/fphar.2023.1188062
Received
16 March 2023
Accepted
16 March 2023
Published
03 April 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2023
Updates
Copyright
© 2023 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.